These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

415 related articles for article (PubMed ID: 32340927)

  • 1. Memantine Effects on Electroencephalographic Measures of Putative Excitatory/Inhibitory Balance in Schizophrenia.
    Molina JL; Voytek B; Thomas ML; Joshi YB; Bhakta SG; Talledo JA; Swerdlow NR; Light GA
    Biol Psychiatry Cogn Neurosci Neuroimaging; 2020 Jun; 5(6):562-568. PubMed ID: 32340927
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Single-Dose Memantine Improves Cortical Oscillatory Response Dynamics in Patients with Schizophrenia.
    Light GA; Zhang W; Joshi YB; Bhakta S; Talledo JA; Swerdlow NR
    Neuropsychopharmacology; 2017 Dec; 42(13):2633-2639. PubMed ID: 28425497
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of acute memantine administration on MATRICS Consensus Cognitive Battery performance in psychosis: Testing an experimental medicine strategy.
    Bhakta SG; Chou HH; Rana B; Talledo JA; Balvaneda B; Gaddis L; Light GA; Swerdlow NR
    Psychopharmacology (Berl); 2016 Jun; 233(12):2399-410. PubMed ID: 27076209
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of NMDA receptor antagonist memantine on mismatch negativity.
    Korostenskaja M; Nikulin VV; Kicić D; Nikulina AV; Kähkönen S
    Brain Res Bull; 2007 May; 72(4-6):275-83. PubMed ID: 17452287
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized, placebo-controlled study of memantine as adjunctive treatment in patients with schizophrenia.
    Lieberman JA; Papadakis K; Csernansky J; Litman R; Volavka J; Jia XD; Gage A;
    Neuropsychopharmacology; 2009 Apr; 34(5):1322-9. PubMed ID: 19005465
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Memantine Effects On Sensorimotor Gating and Mismatch Negativity in Patients with Chronic Psychosis.
    Swerdlow NR; Bhakta S; Chou HH; Talledo JA; Balvaneda B; Light GA
    Neuropsychopharmacology; 2016 Jan; 41(2):419-30. PubMed ID: 26062785
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preliminary Evidence that Memantine Enhances Prepulse Effects on Startle Magnitude and Latency in Patients with Alzheimer's Disease.
    Swerdlow NR; Joshi YB; Sprock J; Talledo J; Molina JL; Delano-Wood L; Iwanaga D; Kotz JE; Huege S; Léger GC; Light GA
    J Alzheimers Dis; 2023; 91(1):355-362. PubMed ID: 36404550
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is Memantine Effective as an NMDA-Receptor Antagonist in Adjunctive Therapy for Schizophrenia?
    Kikuchi T
    Biomolecules; 2020 Jul; 10(8):. PubMed ID: 32751985
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Memantine protects thalamocortical hyper-glutamatergic transmission induced by NMDA receptor antagonism via activation of system xc.
    Okada M; Fukuyama K; Kawano Y; Shiroyama T; Ueda Y
    Pharmacol Res Perspect; 2019 Feb; 7(1):e00457. PubMed ID: 30784207
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of combined treatment with naltrexone and memantine on alcohol drinking behaviors: a phase II randomized crossover trial.
    Krishnan-Sarin S; O'Malley SS; Franco N; Cavallo DA; Tetrault JM; Shi J; Gueorguieva R; Pittman B; Krystal JH
    Neuropsychopharmacology; 2020 Jan; 45(2):319-326. PubMed ID: 31590179
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of memantine in children with autism spectrum disorder: Results from three phase 2 multicenter studies.
    Hardan AY; Hendren RL; Aman MG; Robb A; Melmed RD; Andersen KA; Luchini R; Rahman R; Ali S; Jia XD; Mallick M; Lateiner JE; Palmer RH; Graham SM
    Autism; 2019 Nov; 23(8):2096-2111. PubMed ID: 31027422
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improvement of negative and positive symptoms in treatment-refractory schizophrenia: a double-blind, randomized, placebo-controlled trial with memantine as add-on therapy to clozapine.
    de Lucena D; Fernandes BS; Berk M; Dodd S; Medeiros DW; Pedrini M; Kunz M; Gomes FA; Giglio LF; Lobato MI; Belmonte-de-Abreu PS; Gama CS
    J Clin Psychiatry; 2009 Oct; 70(10):1416-23. PubMed ID: 19906345
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Memantine effects on auditory discrimination and training in schizophrenia patients.
    Swerdlow NR; Bhakta SG; Talledo J; Kotz J; Roberts BZ; Clifford RE; Thomas ML; Joshi YB; Molina JL; Light GA
    Neuropsychopharmacology; 2020 Dec; 45(13):2180-2188. PubMed ID: 32961542
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of the reinforcing and discriminative stimulus properties of the low-affinity N-methyl-D-aspartate channel blocker memantine.
    Nicholson KL; Jones HE; Balster RL
    Behav Pharmacol; 1998 May; 9(3):231-43. PubMed ID: 9832937
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Administration of memantine reverses behavioral, histological, and electrophysiological abnormalities in rats subjected to early maternal deprivation.
    Uribe E; Fernández L; Pacheco D; Fernandez L; Nayadoleni N; Eblen-Zajjur A
    J Neural Transm (Vienna); 2019 Jun; 126(6):759-770. PubMed ID: 31049703
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adjunctive memantine for major mental disorders: A systematic review and meta-analysis of randomized double-blind controlled trials.
    Zheng W; Zhu XM; Zhang QE; Cai DB; Yang XH; Zhou YL; Ungvari GS; Ng CH; He SH; Peng XJ; Ning YP; Xiang YT
    Schizophr Res; 2019 Jul; 209():12-21. PubMed ID: 31164254
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Memantine add-on to risperidone for treatment of negative symptoms in patients with stable schizophrenia: randomized, double-blind, placebo-controlled study.
    Rezaei F; Mohammad-Karimi M; Seddighi S; Modabbernia A; Ashrafi M; Salehi B; Hammidi S; Motasami H; Hajiaghaee R; Tabrizi M; Akhondzadeh S
    J Clin Psychopharmacol; 2013 Jun; 33(3):336-42. PubMed ID: 23609382
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Does memantine improve memory in subjects with focal-onset epilepsy and memory dysfunction? A randomized, double-blind, placebo-controlled trial.
    Leeman-Markowski BA; Meador KJ; Moo LR; Cole AJ; Hoch DB; Garcia E; Schachter SC
    Epilepsy Behav; 2018 Nov; 88():315-324. PubMed ID: 30449328
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neurocognitive Outcomes from Memantine: A Pilot, Double-Blind, Placebo-Controlled Trial in Children with Autism Spectrum Disorder.
    Soorya LV; Fogg L; Ocampo E; Printen M; Youngkin S; Halpern D; Kolevzon A; Lee S; Grodberg D; Anagnostou E
    J Child Adolesc Psychopharmacol; 2021 Sep; 31(7):475-484. PubMed ID: 34543081
    [No Abstract]   [Full Text] [Related]  

  • 20. Auditory System Target Engagement During Plasticity-Based Interventions in Schizophrenia: A Focus on Modulation of N-Methyl-D-Aspartate-Type Glutamate Receptor Function.
    Kantrowitz JT; Swerdlow NR; Dunn W; Vinogradov S
    Biol Psychiatry Cogn Neurosci Neuroimaging; 2018 Jul; 3(7):581-590. PubMed ID: 29656951
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.